focus -WSS

focus

author：leisure time 2025-09-29 01:38:58 - browse：12229

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

knowledge

WSS

'Null' research findings aren't empty of meaning. Let's publish them

Chris Christie meets with Zelenskyy during Ukraine trip

Study says nonprofit hospitals fall short in charity care spending

Alnylam reports growth in sales of rare disease treatments

A controversial new treatment promises to make little people taller

FDA's naming rule on biosimilars has undermined competition

focus

focus

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

A controversial new treatment promises to make little people taller

Heart attack and stroke risk calculators need revising

Covid vaccine financial winners and losers, from Pfizer to Novavax

Jerome Adams on the need for new antivirals for Covid

Oprah kicked off a national conversation on obesity. Let's have it

BioMarin wins approval for gene therapy to treat hemophilia A

2 officers injured in shooting in Orlando, police say

Cancer drug shortages should be causing more outrage

2 officers injured in shooting in Orlando, police say

entertainment

The Readout: Lenmeldy, GLP

Alnylam reports growth in sales of rare disease treatments

The a glaring gap in research on serious mental illness and primary care

Flint parents haunted by uncertainty, fears of lead poisoning

Why the world’s most expensive drug might be worth the price

A controversial new treatment promises to make little people taller

hotspot

entertainment

knowledge

focus